Open AccessPhase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma
Author(s) -
Yutaka Fujiwara,
Yasuo Takahashi,
Minoru Okada,
Takumi Kishimoto,
Shunsuke Kondo,
Koshi Fujikawa,
Manabu Hayama,
Masatoshi Sugeno,
Shinya Ueda,
Keiko Komuro,
Mark C. Lanasa,
Takashi Nakano
Publication year - 2022
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1093/oncolo/oyac099
Subject(s) - tremelimumab , durvalumab , medicine , discontinuation , tolerability , mesothelioma , cohort , adverse effect , oncology , cancer , immunotherapy , nivolumab , pathology , ipilimumab
The primary objective of this phase I, open-label trial was to assess safety and tolerability of tremelimumab monotherapy and combination therapy with durvalumab in Japanese patients with advanced cancer. Tremelimumab is a fully human monoclonal antibody against CTLA-4 in clinical trials; durvalumab is a monoclonal antibody against PD-L1 for the treatment of bladder and lung cancer.